<DOC>
	<DOCNO>NCT01619059</DOCNO>
	<brief_summary>The purpose study learn BMS-477118 ( Saxagliptin ) part triple combination therapy improve ( decrease ) hemoglobin A1c patient type 2 diabetes 24 week treatment compare 2 drug oral antidiabetic therapy . The safety treatment also study .</brief_summary>
	<brief_title>Safety Efficacy Saxagliptin Triple Therapy Treat Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion Criteria 1 . Signed Written Informed Consent ) Subjects must willing able give sign date write informed consent . 2 . Target Population 1 . Subjects T2DM inadequate glycemic control , define central laboratory HbA1c ≥ 8.0 ≤ 11.5 % obtain screen visit ( ie Week 18 visit ) 2 . Stable metformin therapy least 8 week prior screen visit dose ≥ 1500 mg per day . 3 . Cpeptide ≥ 1.0 ng/mL ( 0.34 nmol/L ) screen visit . 4 . BMI ≤ 45.0 kg/m2 screen visit . 3 . Age Reproductive Status 1 . Men woman , age ≥ 18 year old time screen visit . 2 . Women childbearing potential ( WOCBP ) must use acceptable method contraception avoid pregnancy throughout study manner risk pregnancy minimize . See Section 3.3.3 definition WOCBP . 3 . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 24 hour prior start investigational product . 4 . Women must breastfeed 5 . Sexually active fertile men must use effective birth control partner WOCBP . Exclusion Criteria 1 . Target Disease Exceptions 1 . History diabetes insipidus 2 . Symptoms poorly control diabetes would preclude participation trial include limited mark polyuria polydipsia great 10 % weight loss three month prior screen , sign symptom . 3 . History diabetic ketoacidosis hyperosmolar nonketotic coma . 2 . Medical History Concurrent Diseases 1 . History bariatric surgery lapband procedure within 12 month prior screen . 2 . Any unstable endocrine , psychiatric rheumatic disorder judge Investigator . 3 . Subject , judgment investigator , may risk dehydration volume depletion may affect interpretation efficacy safety data concomitant use loop diuretic country recommend per Dapagliflozin label . 4 . Subject currently abuse alcohol drug do within last 6 month . Acute Vascular Event : 5 . Uncontrolled hypertension define systolic blood pressure ( SBP ) ≥ 160 mmHg and/or diastolic blood pressure ( DBP ) ≥ 100 mmHg . Note : Subjects SBP ≥ 160mmHg &lt; 180mmHg DBP ≥ 100 mmHg &lt; 110mmHg able enter leadin period , provide hypertension treatment adjust deemed appropriate investigator . These subject randomize blood pressure remain SBP ≥ 160 mmHg DBP ≥ 100 mmHg measure Day 1 . 6 . Cardiovascular Disease within 3 month screen visit [ ie myocardial infarction , cardiac surgery revascularization ( CABG/PTCA ) , unstable angina , stroke transient ischemic attack ( TIA ) ] . 7 . Congestive heart failure New York Association ( NYHA ) class IV ( see Appendix 1 ) , unstable acute congestive heart failure . Note : eligible patient congestive heart failure , especially diuretic therapy , careful monitoring volume status throughout study . Renal Diseases : 8 . Moderate severe impairment renal function [ define eGFR &lt; 60 mL/min/1.73 m2 ( estimate MDRD ) serum creatinine ( Scr ) ≥ 1.5 mg/dL male ≥ 1.4 mg/dL female . ] 9 . Conditions congenital renal glucosuria Hepatic Diseases : 10 . Significant hepatic disease , include , limited , chronic active hepatitis and/or severe hepatic insufficiency , include subject ALT and/or AST &gt; 3x ULN Total Bilirubin &gt; 2.5 x ULN . Hematological Oncological Disease/Conditions 11 . History hemoglobinopathy , exception sickle cell trait ( SA ) thalassemia minor ; chronic recurrent hemolysis . 12 . Malignancy within 5 year screen visit ( exception treat basal cell treat squamous cell carcinoma ) 13 . Known immunocompromised status , include limited , individual undergo organ transplantation positive human immunodeficiency virus . 14 . Donation blood blood product blood bank , blood transfusion , participation clinical study require withdrawal &gt; 400 mL blood 6 month prior screen visit . Prohibited treatment therapy 15 . Administration antihyperglycemic therapy , metformin , 14 day ( consecutive ) 12 week prior screen , well previous participation DPP4 SGLT2 inhibitor trial exclusion criterion . 16 . Current treatment potent cytochrome P450 3A4/5 inhibitor ( country dose adjustment would require saxagliptin label ) . 17 . Administration investigational drug participation interventional clinical study within 30 day plan screen study . Subjects fail satisfy eligibility criterion screen enter leadin openlabel period CV181169 MB102129 study specifically , need wait 30 day . 3 . Physical Laboratory Test Findings 1 . Hemoglobin ≤ 11.0 g/dL ( 110 g/L ) men ; hemoglobin ≤ 10.0 g/dL ( 100 g/L ) woman 2 . Male subject microscopic hematuria present Week 18 Week 16 AND common cause confirm . Male subject confirm common cause enter openlabel phase document negative result hematuria microscopic urinalysis perform central laboratory . NOTE : Female subject hematuria enter openlabel phase randomize , investigate accord local standard best clinical practice . ( See Appendix 3 ) 3 . Other central laboratory test finding : Abnormal free T4 value . Abnormal thyroid stimulate hormone ( TSH ) value screen evaluate free T4 . Subjects abnormal free T4 value exclude . Positive hepatitis B surface antigen Positive antihepatitis C virus antibody 4 . Allergies Adverse Drug Reaction ) Subjects contraindication therapy outline saxagliptin dapagliflozin Investigator Brochure , local saxagliptin dapagliflozin package insert local metformin package insert , include current treatment potent cytochrome P450 3A4/5 inhibitor ( country dose adjustment would require local saxagliptin label ) . 5 . Sex Reproductive Status ) Women pregnant 6 . Other Exclusion Criteria 1 . Prisoners subject involuntarily incarcerate . 2 . Subject compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>